KDM6B and acute myeloid leukemia: KDM6B-specific pharmacological inhibitor, GSK-J4, dramatically induced anti-proliferative effects in AML cell lines and freshly isolated BM mononuclear cells (MNCs) from AML patients along with increasing levels of H3K27me3.